VDR and breast carcinoma: PTPN3 was also reported in breast cancer by dephosphorylating the epidermal growth factor receptor (EGFR), increasing sensitivity to tyrosine kinase inhibitors (Ma et al., 2015), and by regulation of the vitamin D receptor expression and stability, which stimulates breast cancer growth (Zhi et al., 2011).